ArticleAME case reports2026
Sustained metabolic response in metastatic melanoma after intraperitoneal ozone therapy: a case report.
Article in AME case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Metastatic melanoma remains a therapeutic challenge despite major advances in immunotherapy and targeted therapies. Immune checkpoint inhibitors and BRAF/MEK inhibitors have improved survival in selected patients; however, their use may be limited by immune-related adverse events, acquired resistance, deterioration in quality of life, and economic burden. Intraperitoneal ozone therapy (IPO Case Description: A 66-year-old woman with a history of cutaneous melanoma developed extensive metastatic disease involving subcutaneous, muscular, pulmonary, pleural, and left adrenal sites. Disease progression was documented after adjuvant pembrolizumab, and targeted therapy with dabrafenib plus trametinib was discontinued because of clinically significant systemic toxicity. In June 2024, the patient initiated high-dose IPO Conclusions: In this case, high-dose IPO
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.